Hsp90 inhibitors sensitise human colon cancer cells to topoisomerase i poisons by depletion of key anti-apoptotic and cell cycle checkpoint proteins

Biochemical Pharmacology

Volumn 83, Issue 3, 2012, Pages 355-367

  McNamara, Anne V ^a,b   Barclay, Monica ^a,c   Watson, Alastair J M ^a,d   Jenkins, John R ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c School of Sport and Exercise Sciences   (United Kingdom)

^d UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

17AAG; Hsp90; Irinotecan; P53; Topoisomerase I; Topotecan

Indexed keywords

GELDANAMYCIN; HEAT SHOCK PROTEIN 90 INHIBITOR; HYCAMPTIN; IRINOTECAN; PROTEIN BCL 2; PROTEIN P53; RADICICOL; TOPOTECAN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL STRAIN HCT116; CHEMOSENSITIZATION; COLON CANCER; CONTROLLED STUDY; DATA ANALYSIS; DRUG POTENTIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; UPREGULATION;

APOPTOSIS REGULATORY PROTEINS; BENZOQUINONES; CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; COLONIC NEOPLASMS; DNA TOPOISOMERASES, TYPE I; DRUG THERAPY, COMBINATION; HCT116 CELLS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; TOPOISOMERASE I INHIBITORS;

EID: 84455202283     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.11.017     Document Type: Article

References (61)

1. J.C. Wang Cellular roles of DNA topoisomerases: a molecular perspective Nat Rev Mol Cell Biol 3 2002 430 440 (Pubitemid 34685700)
2. T. Furuta, R.L. Hayward, L.H. Meng, H. Takemura, G.J. Aune, and W.M. Bonner p21CDKN1A allows the repair of replication-mediated DNA double-strand breaks induced by topoisomerase I and is inactivated by the checkpoint kinase inhibitor 7-hydroxystaurosporine Oncogene 25 2006 2839 2849 (Pubitemid 43739234)
3. N.M. Baker, R. Rajan, and A. Mondragon Structural studies of type I topoisomerases Nucleic Acids Res 37 2009 693 701
4. J.M. Fortune, and N. Osheroff Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice Prog Nucleic Acid Res Mol Biol 64 2000 221 253
5. C.R. Barker, J. Hamlett, S.R. Pennington, F. Burrows, K. Lundgren, and R. Lough The topoisomerase II-Hsp90 complex: a new chemotherapeutic target Int J Cancer 118 2006 2685 2693 (Pubitemid 43673345)
6. C.R. Barker, A.V. McNamara, S.A. Rackstraw, D.E. Nelson, M.R. White, and A.J. Watson Inhibition of Hsp90 acts synergistically with topoisomerase II poisons to increase the apoptotic killing of cells due to an increase in topoisomerase II mediated DNA damage Nucleic Acids Res 34 2006 1148 1157
7. W. Zhang, M. Hirshberg, S.H. McLaughlin, G.A. Lazar, J.G. Grossmann, and P.R. Nielsen Biochemical and structural studies of the interaction of Cdc37 with Hsp90 J Mol Biol 340 2004 891 907 (Pubitemid 38832524)
8. A. Kamal, L. Thao, J. Sensintaffar, L. Zhang, M.F. Boehm, and L.C. Fritz A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors Nature 425 2003 407 410 (Pubitemid 37187270)
9. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
10. P. Workman, F. Burrows, L. Neckers, and N. Rosen Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress Ann N Y Acad Sci 1113 2007 202 216 (Pubitemid 350015011)
11. Y. Pommier, E. Leo, H. Zhang, and C. Marchand DNA topoisomerases and their poisoning by anticancer and antibacterial drugs Chem Biol 17 2010 421 433
12. Y. Pommier Topoisomerase I inhibitors: camptothecins and beyond Nat Rev Cancer 6 2006 789 802 (Pubitemid 44450467)
13. W.G. Nelson, and M.B. Kastan DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways Mol Cell Biol 14 1994 1815 1823 (Pubitemid 24074576)
14. R.G. Shao, C.X. Cao, T. Shimizu, P.M. O'Connor, K.W. Kohn, and Y. Pommier Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function Cancer Res 57 1997 4029 4035 (Pubitemid 27427693)
15. Y. Pommier, C. Redon, V.A. Rao, J.A. Seiler, O. Sordet, and H. Takemura Repair of and checkpoint response to topoisomerase I-mediated DNA damage Mutat Res 532 2003 173 203 (Pubitemid 37487853)
16. W.Y. Siu, A. Lau, T. Arooz, J.P. Chow, H.T. Ho, and R.Y. Poon Topoisomerase poisons differentially activate DNA damage checkpoints through ataxia-telangiectasia mutated-dependent and -independent mechanisms Mol Cancer Ther 3 2004 621 632 (Pubitemid 39193741)
17. C.B. Jones, M.K. Clements, S. Wasi, and S.S. Daoud Sensitivity to camptothecin of human breast carcinoma and normal endothelial cells Cancer Chemother Pharmacol 40 1997 475 483 (Pubitemid 27389288)
18. R.H. te Poele, and S.P. Joel Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines Br J Cancer 81 1999 1285 1293
19. Y. Zhou, F.G. Gwadry, W.C. Reinhold, L.D. Miller, L.H. Smith, and U. Scherf Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects Cancer Res 62 2002 1688 1695 (Pubitemid 34408490)
20. S.S. Daoud, P.J. Munson, W. Reinhold, L. Young, V.V. Prabhu, and Q. Yu Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study Cancer Res 63 2003 2782 2793 (Pubitemid 36667149)
21. P. Pourquier, C. Gioffre, G. Kohlhagen, Y. Urasaki, F. Goldwasser, and L.W. Hertel Gemcitabine (2′,2′-difluoro-2′-deoxycytidine), an antimetabolite that poisons topoisomerase I Clin Cancer Res 8 2002 2499 2504 (Pubitemid 34856331)
22. S.J. Arlander, A.K. Eapen, B.T. Vroman, R.J. McDonald, D.O. Toft, and L.M. Karnitz Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress J Biol Chem 278 2003 52572 52577 (Pubitemid 38035854)
23. M.A. Bjornsti, and N. Osheroff Introduction to DNA topoisomerases Methods Mol Biol 94 1999 1 8
24. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, and D. Vistica New colorimetric cytotoxicity assay for anticancer-drug screening J Natl Cancer Inst 82 1990 1107 1112 (Pubitemid 20213250)
25. W. Voigt Sulforhodamine B assay and chemosensitivity Methods Mol Med 110 2005 39 48
26. R.J. Tallarida The interaction index: a measure of drug synergism Pain 98 2002 163 168 (Pubitemid 34722478)
27. A. Munshi, M. Hobbs, and R.E. Meyn Clonogenic cell survival assay Methods Mol Med 110 2005 21 28
28. R.J. Tallarida, D.J. Stone Jr., and R.B. Raffa Efficient designs for studying synergistic drug combinations Life Sci 61 1997 PL 417 PL 425
29. D. Subramanian, C.S. Furbee, and M.T. Muller ICE bioassay. Isolating in vivo complexes of enzyme to DNA Methods Mol Biol 95 2001 137 147
30. T. Furuta, H. Takemura, Z.Y. Liao, G.J. Aune, C. Redon, and O.A. Sedelnikova Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes J Biol Chem 278 2003 20303 20312 (Pubitemid 36799229)
31. X. Huang, F. Traganos, and Z. Darzynkiewicz DNA damage induced by DNA topoisomerase I- and topoisomerase II-inhibitors detected by histone H2AX phosphorylation in relation to the cell cycle phase and apoptosis Cell Cycle 2 2003 614 619
32. F. Burrows, H. Zhang, and A. Kamal Hsp90 activation and cell cycle regulation Cell Cycle 3 2004 1530 1536 (Pubitemid 40521406)
33. G. Juan, F. Traganos, W.M. James, J.M. Ray, M. Roberge, and D.M. Sauve Histone H3 phosphorylation and expression of cyclins A and B1 measured in individual cells during their progression through G2 and mitosis Cytometry 32 1998 71 77 (Pubitemid 28246753)
34. A.N. Tse, T.N. Sheikh, H. Alan, T.C. Chou, and G.K. Schwartz 90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1 Mol Pharmacol 75 2009 124 133
35. R.J. Youle, and A. Strasser The BCL-2 protein family: opposing activities that mediate cell death Nat Rev Mol Cell Biol 9 2008 47 59
36. G.J. Rautureau, C.L. Day, and M.G. Hinds Intrinsically disordered proteins in bcl-2 regulated apoptosis Int J Mol Sci 11 2010 1808 1824
37. J. Yang, X. Liu, K. Bhalla, C.N. Kim, A.M. Ibrado, and J. Cai Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked Science 275 1997 1129 1132 (Pubitemid 27097312)
38. S. Dias, S.V. Shmelkov, G. Lam, and S. Rafii VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition Blood 99 2002 2532 2540 (Pubitemid 34525442)
39. C. Cohen-Saidon, I. Carmi, A. Keren, and E. Razin Antiapoptotic function of Bcl-2 in mast cells is dependent on its association with heat shock protein 90beta Blood 107 2006 1413 1420 (Pubitemid 43242376)
40. S.J. Du, H. Li, Y. Bian, and Y. Zhong Heat-shock protein 90alpha1 is required for organized myofibril assembly in skeletal muscles of zebrafish embryos Proc Natl Acad Sci USA 105 2008 554 559 (Pubitemid 351171746)
41. X. Du, R. Mi, Q. Qu, Y. Qu, and T. Yue Effects of geldanamycin on expression of Bcl-2 in human cervical cancer HeLa cells Chin J Clin Oncol 5 2008 113 117
42. P. Pandey, A. Saleh, A. Nakazawa, S. Kumar, S.M. Srinivasula, and V. Kumar Negative regulation of cytochrome c-mediated oligomerization of Apaf-1 and activation of procaspase-9 by heat shock protein 90 EMBO J 19 2000 4310 4322 (Pubitemid 30623742)
43. K. Cain, S.B. Bratton, C. Langlais, G. Walker, D.G. Brown, and X.M. Sun Apaf-1 oligomerizes into biologically active approximately 700-kDa and inactive approximately 1.4-MDa apoptosome complexes J Biol Chem 275 2000 6067 6070 (Pubitemid 30129888)
44. M. Gupta, S. Fan, Q. Zhan, K.W. Kohn, P.M. O'Connor, and Y. Pommier Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells Clin Cancer Res 3 1997 1653 1660 (Pubitemid 27431576)
45. Y. Wang, S. Zhu, T.F. Cloughesy, and L.M. Liau Mischel PS. p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition Oncogene 23 2004 1283 1290 (Pubitemid 38297183)
46. R. Magrini, M.R. Bhonde, M.L. Hanski, M. Notter, H. Scherubl, and C.R. Boland Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status Int J Cancer 101 2002 23 31 (Pubitemid 34832993)
47. Z. Han, W. Wei, S. Dunaway, J.W. Darnowski, P. Calabresi, and J. Sedivy Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin J Biol Chem 277 2002 17154 17160 (Pubitemid 34967748)
48. F. Schmidt, J. Rieger, J. Wischhusen, U. Naumann, and M. Weller Glioma cell sensitivity to topotecan: the role of p53 and topotecan-induced DNA damage Eur J Pharmacol 412 2001 21 25 (Pubitemid 32149765)
49. M.T. Tomicic, M. Christmann, and B. Kaina Topotecan-triggered degradation of topoisomerase I is p53-dependent and impacts cell survival Cancer Res 65 2005 8920 8926 (Pubitemid 41377382)
50. M. Oggionni, S. Pilotti, S. Suardi, A. Ditto, C. Luoni, and L. Mariani p53 Gene status and response to topotecan-containing chemotherapy in advanced ovarian carcinoma Oncology 69 2005 154 158 (Pubitemid 41376914)
51. K. Flatten, N.T. Dai, B.T. Vroman, D. Loegering, C. Erlichman, and L.M. Karnitz The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons J Biol Chem 280 14 2005 14349 14355 Epub 2005 Feb 7 (Pubitemid 40517339)
52. A.N. Tse, T.N. Sheikh, H. Alan, T.C. Chou, and G.K. Schwartz 90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1 Mol Pharmacol 75 1 2009 124 133 Epub 2008 Sep 26
53. L.D. Mayer, and A.S. Janoff Optimizing combination chemotherapy by controlling drug ratios Mol Interv 7 2007 216 223 (Pubitemid 47437268)
54. M.V. Blagosklonny, T. Fojo, K.N. Bhalla, J.S. Kim, J.B. Trepel, and W.D. Figg The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy Leukemia 15 2001 1537 1543 (Pubitemid 32994672)
55. Munster PN, Basso A, Solit D, Norton L, Rosen N. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: Sausville EA. Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Clin Cancer Res 2001;7:2155-8.
56. Clin Cancer Res 2001;7:2228-36.
57. Y. Shi, X. Liu, E.K. Han, R. Guan, A.R. Shoemaker, and A. Oleksijew Optimal classes of chemotherapeutic agents sensitized by specific small-molecule inhibitors of akt in vitro and in vivo Neoplasia 7 2005 992 1000
58. A.N. Tse, D.S. Klimstra, M. Gonen, M. Shah, T. Sheikh, and R. Sikorski A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors Clin Cancer Res 14 2008 6704 6711
59. P.J. Houghton, G.S. Germain, F.C. Harwood, J.D. Schuetz, C.F. Stewart, and E. Buchdunger Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro Cancer Res 64 2004 2333 2337 (Pubitemid 38523883)
60. J.R. Jenkins A proteomic approach to identifying new drug targets (potentiating topoisomerase II poisons) Br J Radiol 81 Spec. No. 1 2008 S69 S77
61. S.S. Dharap, P. Chandna, Y. Wang, J.J. Khandare, B. Qiu, and S. Stein Molecular targeting of BCL2 and BCLXL proteins by synthetic BCL2 homology 3 domain peptide enhances the efficacy of chemotherapy J Pharmacol Exp Ther 316 2006 992 998 (Pubitemid 43345270)